GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells

Hdl Handle:
http://hdl.handle.net/10034/614989
Title:
GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells
Authors:
Yacqub-Usman, Kiren; Pickard, Mark R.; Williams, Gwyn T.
Abstract:
Background There is a need to develop new therapies for castrate-resistant prostate cancer (CRPC) and growth arrest-specific 5 (GAS5) long non-coding RNA (lncRNA), which riborepresses androgen receptor action, may offer novel opportunities in this regard. GAS5 lncRNA expression declines as prostate cancer cells acquire castrate-resistance, and decreased GAS5 expression attenuates the responses of prostate cancer cells to apoptotic stimuli. Enhancing GAS5 lncRNA expression may therefore offer a strategy to improve the effectiveness of chemotherapeutic agents. GAS5 is a member of the 5' terminal oligopyrimidine gene family, and we have therefore examined if mTOR inhibition can enhance cellular GAS5 levels in prostate cancer cells. In addition, we have determined if GAS5 lncRNA itself is required for mTOR inhibitor action in prostate cancer cells, as recently demonstrated in lymphoid cells. Method The effects of mTOR inhibitors on GAS5 lncRNA expression and cell proliferation were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNA and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. Results Treatment with rapamycin and rapalogues increased cellular GAS5 levels and inhibited culture growth in both androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU145) cells. GAS5 silencing in both LNCaP and 22Rv1 cells decreased their sensitivity to growth inhibition by mTOR inhibitors. Moreover, transfection of GAS5 lncRNA sensitized PC-3 and DU145 cells to mTOR inhibitors, resulting in inhibition of culture growth. Conclusion mTOR inhibition enhances GAS5 transcript levels in some, but not all, prostate cancer cell lines. This may in part be related to endogenous levels of GAS5 expression, which tend to be lower in prostate cancer cells representative of advanced disease, particularly since current findings demonstrate a role for GAS5 lncRNA in mTOR inhibitor action in prostate cancer cells.
Affiliation:
Keele University, United Kingdom
Citation:
Yacqub-Usman, K., Pickard, M., & Williams, G. (2014). GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells. Paper presented at the NCRI Cancer Conference 2014.
Publisher:
NCRI Cancer Conference 2014 Abstracts
Publication Date:
2014
URI:
http://hdl.handle.net/10034/614989
Additional Links:
http://abstracts.ncri.org.uk/abstract/gas5-lncrna-modulates-the-action-of-mtor-inhibitors-in-prostate-cancer-cells-2/
Type:
Meetings and Proceedings
Language:
en
Appears in Collections:
Institute of Medicine

Full metadata record

DC FieldValue Language
dc.contributor.authorYacqub-Usman, Kirenen
dc.contributor.authorPickard, Mark R.en
dc.contributor.authorWilliams, Gwyn T.en
dc.date.accessioned2016-06-29T08:24:02Z-
dc.date.available2016-06-29T08:24:02Z-
dc.date.issued2014-
dc.identifier.citationYacqub-Usman, K., Pickard, M., & Williams, G. (2014). GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells. Paper presented at the NCRI Cancer Conference 2014.en
dc.identifier.otherNA-
dc.identifier.urihttp://hdl.handle.net/10034/614989-
dc.description.abstractBackground There is a need to develop new therapies for castrate-resistant prostate cancer (CRPC) and growth arrest-specific 5 (GAS5) long non-coding RNA (lncRNA), which riborepresses androgen receptor action, may offer novel opportunities in this regard. GAS5 lncRNA expression declines as prostate cancer cells acquire castrate-resistance, and decreased GAS5 expression attenuates the responses of prostate cancer cells to apoptotic stimuli. Enhancing GAS5 lncRNA expression may therefore offer a strategy to improve the effectiveness of chemotherapeutic agents. GAS5 is a member of the 5' terminal oligopyrimidine gene family, and we have therefore examined if mTOR inhibition can enhance cellular GAS5 levels in prostate cancer cells. In addition, we have determined if GAS5 lncRNA itself is required for mTOR inhibitor action in prostate cancer cells, as recently demonstrated in lymphoid cells. Method The effects of mTOR inhibitors on GAS5 lncRNA expression and cell proliferation were determined in a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNA and plasmid constructs was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. Results Treatment with rapamycin and rapalogues increased cellular GAS5 levels and inhibited culture growth in both androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU145) cells. GAS5 silencing in both LNCaP and 22Rv1 cells decreased their sensitivity to growth inhibition by mTOR inhibitors. Moreover, transfection of GAS5 lncRNA sensitized PC-3 and DU145 cells to mTOR inhibitors, resulting in inhibition of culture growth. Conclusion mTOR inhibition enhances GAS5 transcript levels in some, but not all, prostate cancer cell lines. This may in part be related to endogenous levels of GAS5 expression, which tend to be lower in prostate cancer cells representative of advanced disease, particularly since current findings demonstrate a role for GAS5 lncRNA in mTOR inhibitor action in prostate cancer cells.en
dc.language.isoenen
dc.publisherNCRI Cancer Conference 2014 Abstractsen
dc.relation.urlhttp://abstracts.ncri.org.uk/abstract/gas5-lncrna-modulates-the-action-of-mtor-inhibitors-in-prostate-cancer-cells-2/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectGAS5en
dc.subjectprostate canceren
dc.subjectlncRNAen
dc.subjectapoptosisen
dc.subjectmTOR inhibitoren
dc.titleGAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cellsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentKeele University, United Kingdomen
dc.date.accepted2014-07-01-
or.grant.openaccessYesen
rioxxterms.funderUnfundeden
rioxxterms.identifier.projectUnfundeden
rioxxterms.versionAMen
rioxxterms.licenseref.startdate2014-
This item is licensed under a Creative Commons License
Creative Commons
All Items in ChesterRep are protected by copyright, with all rights reserved, unless otherwise indicated.